Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-80 years of age;~* histological diagnosis of primary central nervous system lymphoma;~* B-cell proliferation verified by positive staining for CD20;~* \>=1 measurable lesion.~Exclusion Criteria:~* prior chemotherapy, other than corticosteroids, \>=6 weeks before and after diagnosis or surgery;~* history of prior cranial irradiation;~* evidence of plurisystemic non-Hodgkin's lymphoma;~* other active malignant disease (other than basal cell or squamous cell cancer of skin,or cancer in situ of cervix;~* uncontrolled active infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).